Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
about
Histone methyltransferases: novel targets for tumor and developmental defectsGenetic and Chromosomal Aberrations and Their Clinical Significance in Renal NeoplasmsMedical treatment of renal cancer: new horizonsThe roles of chromatin-remodelers and epigenetic modifiers in kidney cancerComprehensive review of BAP1 tumor predisposition syndrome with report of two new casesGenetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNAMolecular genetics of clear-cell renal cell carcinomaVHL, the story of a tumour suppressor gene.miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinomaSnail heterogeneity in clear cell renal cell carcinoma.Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevanceRole of several histone lysine methyltransferases in tumor development.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Genetic mutations associated with metastatic clear cell renal cell carcinoma.Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.Examining the impact of gene variants on histone lysine methylationNew insights on chromatin modifiers and histone post-translational modifications in renal cell tumours.The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.Inhibitors of Protein Methyltransferases and Demethylases.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation.The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma.Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.Different prognostic roles of tumor suppressor gene BAP1 in cancer: A systematic review with meta-analysis.Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma.Imaging-genomic pipeline for identifying gene mutations using three-dimensional intra-tumor heterogeneity features.Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.A BAP1 Mutation-specific MicroRNA Signature Predicts Clinical Outcomes in Clear Cell Renal Cell Carcinoma Patients with Wild-type BAP1.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications.Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.Serum tissue factor as a biomarker for renal clear cell carcinoma.The epigenetic landscape of clear-cell renal cell carcinoma.
P2860
Q26775027-0A8A1DA0-AF1F-4082-AC7B-6C24345B49C9Q26785930-EC138BE2-A308-4855-B7FB-AA5F4053BD66Q28073174-11467B2F-A185-4C39-9E3F-F6BE31F94CE4Q28083152-FB9040CF-4631-465F-BFD7-303883639619Q28397229-BD72A76C-4479-4ED7-8626-7568C5E40DB1Q33709786-D4A87517-8877-41D4-953B-D5A59539908BQ33729097-7EFCEE29-D3D4-4C51-AC0E-5B4C23612A35Q34455226-84B00D37-0E14-48DB-BE77-6EC8EBE54508Q35551941-5C4B33FC-D2C8-4FC5-96FD-BF33507A15C8Q35677757-7561BFE1-3A1E-49D7-9BAE-AD530CC7B7D2Q35948243-B43BC409-1F42-4014-AE0B-D92D174AB28FQ36105139-04D7E544-B5EB-485C-9EC1-47DE86377705Q36639797-D5848991-4D0C-469E-93A8-2303BD3426ADQ37016755-D9421D33-D416-43A3-9383-A9E9D8FBED4AQ37085985-08E05BAA-60FB-4022-9BA0-D34917A4FA69Q37573538-F333275C-9B67-466E-9076-2719A5B75F12Q38214535-06739556-A9EA-4D1C-A2E8-17378BA406AFQ38294198-6E617D4D-BA5F-4853-B8E8-937327580BF9Q38419495-EB867E2A-DC06-48EC-9FF9-A1853608350DQ38740496-57A771A2-AFED-4645-AAE6-7817A12AAF3AQ38762066-8D6F1658-B52B-4BC4-8D7E-85841947245DQ38810854-DE508A6B-0E4B-4F6C-8701-BBFFCEDDA5B3Q38811459-64CE431E-6162-4DD7-9289-DFF1FA9EB786Q38813611-81DA2BDE-0515-4246-A4E6-01E7FAD7F643Q38843978-A00F4F39-055C-4EAB-9ABA-275A51482488Q38910995-FCAA9B35-AD68-41DF-BEDC-3C1B8F29BE3FQ39118911-FA39AFAA-A21B-47C0-95B3-A3AB3C9A8098Q39608223-2FE0BAD0-454F-4904-AAE8-85E252C3BD46Q40028818-DD5CFAA2-F577-430F-9316-40DC01C0D3DDQ40243097-A9739A8C-BFB6-45E5-A40C-7CBE0C23D776Q41242139-3BE0AF4D-3238-4AC5-969C-54ACDEC2771CQ41574276-D88586D1-9E93-4EF3-B0D0-8EC25E1E1504Q41882621-A4CA9C5D-BC00-4031-A95C-5C9EA8C9D9D3Q42737907-AE458600-6656-43EC-B5DC-8512A2B0EA01Q46856592-3D7B3D1E-FD60-4515-B319-C2109668D36CQ47592158-2B2FDC73-7D51-4DDA-B73B-C143F248C5A4Q47972869-E4D332A5-D613-479B-A9EB-1E03309EB2BAQ48368561-B43149DD-8545-44BB-BA59-6E2C5BA40896Q50323362-52588EF4-14CB-441B-B88D-BD0D982DA478Q51091490-6206FC38-C951-48D5-9DE0-C14D40F0F726
P2860
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@en
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@nl
type
label
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@en
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@nl
prefLabel
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@en
Clinical and pathological impa ...... ear cell renal cell carcinoma.
@nl
P2093
P2860
P50
P356
P1476
Clinical and pathological impa ...... lear cell renal cell carcinoma
@en
P2093
Andreas Claas
Andrew Dunham
Andrew F Slatter
Andrew P May
Anne Warren
Beverley Haynes
Conrad P Lichtenstein
Ian Roberts
Lucy Gossage
Nitzan Rosenfeld
P2860
P356
10.1002/GCC.22116
P577
2013-10-29T00:00:00Z